Loading…
UroGen Pharma Ltd. is projected to rise to $39.34 by 2027, a +34% move from its current price of $29.33. URGN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $28.33 | $29.34 | $30.38 | +0.03% |
| May 30 | $27.93 | $29.35 | $30.83 | +0.06% |
| May 31 | $27.63 | $29.36 | $31.19 | +0.09% |
| Jun 1 | $27.38 | $29.36 | $31.49 | +0.11% |
| Jun 2 | $27.16 | $29.37 | $31.76 | +0.14% |
| Jun 3 | $26.97 | $29.38 | $32.00 | +0.17% |
| Jun 4 | $26.79 | $29.39 | $32.23 | +0.20% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $26.79 | $29.39 | $32.23 | +0.20% |
| Week 2 | $25.84 | $29.45 | $33.56 | +0.40% |
| Week 3 | $25.14 | $29.51 | $34.63 | +0.60% |
| Week 4 | $24.58 | $29.56 | $35.57 | +0.80% |
| Week 5 | $24.09 | $29.62 | $36.42 | +1.00% |
| Week 6 | $23.67 | $29.68 | $37.22 | +1.20% |
| Week 7 | $23.29 | $29.74 | $37.98 | +1.41% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
UroGen Pharma Ltd. is a biotechnology company that develops and commercializes solutions for urothelial and specialty cancers. Its lead product candidates are UGN-103, which is in phase 3 for an intravesical solution, and UGN-104, which is in phase 3 for a pyelocalyceal solution.
The company also develops Jelmyto and Mitomycin-based formulations such as Zusduri, and uses RTGel technology in its portfolio. UroGen was incorporated in 2004 and is headquartered in Princeton, New Jersey.
URGN is currently trading at $28.89 per share.
Its market capitalization is $1.41B and it ranks 2282.
The long-range outlook shows substantial upside, with an average price rising to $74.35 by 2030 and $635.29 by 2050, accompanied by ROIs of 157.4% and 2099%, respectively, signaling a bullish longer-term trajectory.
A major floor 42.0% below — a decisive break under it would weaken the trend.
The nearest floor, 27.1% below — buyers have tended to step in here.
The nearest ceiling, 6.8% above — a clean break opens room to run.
A major ceiling 27.1% above — clearing it would confirm fresh momentum.
Key URGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of URGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $29.56 | Sell | $29.33 | Sell |
| MA 10 | $29.40 | Sell | $29.04 | Buy |
| MA 20 | $27.73 | Buy | $27.82 | Buy |
| MA 50 | $23.32 | Buy | $24.97 | Buy |
| MA 100 | $21.93 | Buy | $23.05 | Buy |
| MA 200 | $21.33 | Buy | $20.94 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.42 | Neutral |
| Stoch RSI (14) | 5.73 | Buy |
| CCI (20) | 44.32 | Neutral |
| Williams %R (14) | -42.19 | Info |
| MACD (12,26,9) | -0.17 | Sell |
| ROC (12) | -0.24 | Sell |
| Bollinger %B (20,2) | 0.65 | Neutral |
| Stochastic %K (14) | 57.81 | Neutral |
| TRIX (15) | 1.20 | Buy |
| Awesome (5,34) | 3.79 | Buy |
| Ultimate (7,14,28) | 58.63 | Neutral |
| Momentum (10) | -0.47 | Sell |
| Aroon Osc (25) | 24.00 | Buy |
| Hull MA (9) | 29.46 | Sell |
| ADX (14) | 27.21 | Buy |
| ATR (14) | 0.88 | Info |
The near-term picture is described as BULLISH, with RSI14 at 60.
The 50-day simple moving average is $22.89 and the 200-day simple moving average is $21.22, with a support level at $20.28 and a resistance level at $31.33.
The 30-day price range spans from $22.65 to $36.86, outlining a defined near-term trading band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $17.00 | $29.33 | $42.40 | 0% | Neutral | |
| $30.36 | $39.34 | $54.49 | +34% | Bullish | |
| $33.31 | $44.74 | $64.73 | +53% | Bullish | |
| $37.66 | $52.14 | $78.09 | +78% | Bullish | |
| $53.10 | $75.53 | $116.44 | +158% | Bullish | |
| $61.20 | $89.24 | $141.10 | +204% | Bullish | |
| $67.82 | $101.24 | $163.73 | +245% | Bullish | |
| $79.83 | $121.82 | $201.08 | +315% | Bullish | |
| $75.54 | $117.73 | $198.03 | +301% | Bullish | |
| $81.24 | $129.21 | $221.14 | +341% | Bullish | |
| $133.87 | $233.87 | $430.37 | +697% | Bullish | |
| $307.62 | $635.96 | $1,299.24 | +20.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $17.00 | $29.33 | $34.71 | +0.00% |
| June 2026 | $25.73 | $30.41 | $36.92 | +3.67% |
| July 2026 | $25.20 | $30.10 | $37.17 | -1.00% |
| August 2026 | $25.10 | $30.24 | $37.83 | +0.44% |
| September 2026 | $26.28 | $31.89 | $40.32 | +5.45% |
| October 2026 | $26.78 | $32.70 | $41.75 | +2.57% |
| November 2026 | $26.16 | $32.12 | $41.35 | -1.78% |
| December 2026 | $26.46 | $32.68 | $42.40 | +1.73% |
Click any year to see its month-by-month URGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, URGN is projected to trade between $17.00 and $42.40, averaging $29.33 — a potential gain of 0% from today's $29.33. A consolidation phase looks the most probable path here.
UroGen Pharma Ltd.'s 2027 outlook centres on $39.34, within a $30.36 to $54.49 range. That is up +34% on the projected 2026 average. That marks a +34% change versus current levels. Momentum favours further upside here.
By 2028, URGN could reach as high as $64.73, with a base case around $44.74 and support toward $33.31 — roughly +53% from $29.33. Buyers look set to stay in control over this stretch.
Expect URGN to range from $37.66 to $78.09 through 2029. The $52.14 average target implies a +78% move from current prices. That is up +17% on the projected 2028 average. Momentum favours further upside here.
The URGN price prediction for 2030 points to an average of $75.53 (low $53.10, high $116.44) — a potential gain of +158% on today's $29.33. Buyers look set to stay in control over this stretch.
In 2031, URGN is projected to trade between $61.20 and $141.10, averaging $89.24 — a potential gain of +204% from today's $29.33. That is up +18% on the projected 2030 average. Momentum favours further upside here.
UroGen Pharma Ltd.'s 2032 outlook centres on $101.24, within a $67.82 to $163.73 range. That is up +13% on the projected 2031 average. That marks a +245% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, URGN could reach as high as $201.08, with a base case around $121.82 and support toward $79.83 — roughly +315% from $29.33. Momentum favours further upside here.
Expect URGN to range from $75.54 to $198.03 through 2034. The $117.73 average target implies a +301% move from current prices. That is -3% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The URGN price prediction for 2035 points to an average of $129.21 (low $81.24, high $221.14) — a potential gain of +341% on today's $29.33. Momentum favours further upside here.
In 2040, URGN is projected to trade between $133.87 and $430.37, averaging $233.87 — a potential gain of +697% from today's $29.33. That is up +81% on the projected 2035 average. Buyers look set to stay in control over this stretch.
UroGen Pharma Ltd.'s 2050 outlook centres on $635.96, within a $307.62 to $1,299.24 range. That is up +172% on the projected 2040 average. That marks a +20.7x change versus current levels. Momentum favours further upside here.
Investing $1,000 in URGN today (≈ 34.094783 URGN) could be worth
$21,682.93
+$20,682.93 (+2068%) by 2050 · US Dollar
Based on the average projected URGN price of $635.96 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in URGNwould be worth at today's price.
$1,000 invested in URGN on May 27, 2025 (≈ 254.452922 URGN) would be worth
$7,463.1
+$6,463.1 (+646.3%) today · 7.46× · US Dollar
Based on a URGN entry price of $3.93 vs. today's $29.33.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $30.22 | $970.55 | -2.9% |
| 1 month ago | $23.77 | $1,233.91 | +23.4% |
| 3 months ago | $21.18 | $1,384.8 | +38.5% |
| 6 months ago | $28.81 | $1,018.05 | +1.8% |
| 1 year ago | $3.93 | $7,463.1 | +646.3% |
| All time (5.0y) ago | $18.86 | $1,555.14 | +55.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our URGN forecast.
Our base-case forecast reaches $59.00 around 2030.
Implied market cap at $59.00: $2.87B
The multi-year forecast paints a bullish path, with notable targets at 2030, 2040, and 2050.
In 2030, the average price is projected to be $74.35 with a return on investment of 157.4%.
In 2040, the average price is projected to be $229.00 with a return on investment of 692.6%.
In 2050, the average price is projected to be $635.29 with a return on investment of 2099%. These figures imply substantial long-term upside but are estimates, not guarantees, and depend on a range of market and company-specific factors.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $74.35 with an ROI of 157.4% and bullish sentiment.
Forecasts show bullish sentiment from 2027 onward with rising averages (e.g., 2027 $38.58, 2028 $43.79, 2029 $51.45, 2030 $74.35), but these are estimates, not guarantees.
Yes. The forecast indicates an average near $100.87 by 2032 with an ROI of 249.2%.
Current price is $28.89 and market capitalization is $1.41B.
The 2050 forecast shows an average price of $635.29 with a max of $1,330.32 and an ROI of 2099%, with bullish sentiment.
UroGen Pharma Ltd. Community Discussion
0Share your UroGen Pharma Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.